Abstract
The rise of multi-drug resistant and extensively drug resistant M. tuberculosis around the world poses a great threat to human health, and necessitates development of new, effective and inexpensive anti-tubercular agents. The availability of knowledge on molecular biology of M. tuberculosis infection coupled with whole genome sequences, transcriptomic, proteomic and metabolomic data sets have provided insights on the genes/proteins indispensable for initiation and maintenance of persistence, cross-talk with and/or sensing the host immune response, and finally the reactivation of persistent M. tuberculosis to a growing state. The review will focus on analysis of current state of M. tuberculosis genomic resources, host-pathogen interaction studies in the context of pathogen persistence, and the efforts made or required in the development and utilization of computational tools, models and metabolic network analyses to speed up the process of drug target discovery, particularly eradicating the dormant infections.
Keywords: M. tuberculosis, drug, targets, resistance, persistence, dormancy, genomics, computational, protein-network.
Current Pharmaceutical Design
Title:Can Mycobacterial Genomics Generate Novel Targets as Speed-Breakers Against the Race for Drug Resistance
Volume: 20 Issue: 27
Author(s): R.S. Chauhan, S.K. Chanumolu, Chittaranjan Rout and Rahul Shrivastava
Affiliation:
Keywords: M. tuberculosis, drug, targets, resistance, persistence, dormancy, genomics, computational, protein-network.
Abstract: The rise of multi-drug resistant and extensively drug resistant M. tuberculosis around the world poses a great threat to human health, and necessitates development of new, effective and inexpensive anti-tubercular agents. The availability of knowledge on molecular biology of M. tuberculosis infection coupled with whole genome sequences, transcriptomic, proteomic and metabolomic data sets have provided insights on the genes/proteins indispensable for initiation and maintenance of persistence, cross-talk with and/or sensing the host immune response, and finally the reactivation of persistent M. tuberculosis to a growing state. The review will focus on analysis of current state of M. tuberculosis genomic resources, host-pathogen interaction studies in the context of pathogen persistence, and the efforts made or required in the development and utilization of computational tools, models and metabolic network analyses to speed up the process of drug target discovery, particularly eradicating the dormant infections.
Export Options
About this article
Cite this article as:
Chauhan R.S., Chanumolu S.K., Rout Chittaranjan and Shrivastava Rahul, Can Mycobacterial Genomics Generate Novel Targets as Speed-Breakers Against the Race for Drug Resistance, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118165427
DOI https://dx.doi.org/10.2174/1381612819666131118165427 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in the Chemistry of Saccharins: From Synthetic Novelties Towards Biologically Active Compounds
Current Medicinal Chemistry MRSA Infections: From Classical Treatment to Suicide Drugs
Current Medicinal Chemistry Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Early Life Vitamin D Status and Lung Development
Current Respiratory Medicine Reviews Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Pleural Involvement Due to Metastatic Melanoma: A Rare Complication and Literature Review
Current Respiratory Medicine Reviews Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents
Letters in Drug Design & Discovery Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Aging in Bacteria, Immortality or Not-A Critical Review
Current Aging Science Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology <i>Enoyl-Acyl Carrier Protein Reductase (INHA)</i>: A Remarkable Target to Exterminate Tuberculosis
Anti-Infective Agents Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Current Pharmaceutical Design The Endoplasmic Reticulum Alpha-Glycosidases as Potential Targets for Virus Control
Current Protein & Peptide Science Energy Provisioning and Inflammasome Activation: The Pivotal Role of AMPK in Sterile Inflammation and Associated Metabolic Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Identification of Bostrycin Derivatives as Potential Inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase (MptpB)
Medicinal Chemistry Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Effective Therapy with the Neuroleptic Thioridazine as an Adjunct to Second Line of Defence Drugs, and the Potential that Thioridazine Offers for New Patents that Cover a Variety of “New Uses”
Recent Patents on Anti-Infective Drug Discovery Marine Microbes-Derived Anti-Bacterial Agents
Mini-Reviews in Medicinal Chemistry Applications of Docking and Molecular Dynamic Studies on the Search for New Drugs Against the Biological Warfare Agents Bacillus anthracis and Yersinia pestis
Current Computer-Aided Drug Design